Acepodia obtained FDA IND clearance for ACE-723, a GPC3-targeted dual-payload antibody-drug conjugate. The company plans to begin a Phase I trial in patients with unresectable or metastatic hepatocellular carcinoma, positioning the ADC for first-in-human clinical assessment in a GPC3-driven oncology setting.